Vedolizumab

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)2.62 [0.52, 13.35]-1 study664not evaluable ROB-

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)2.33 [0.95, 5.70]-1 study2264not evaluable ROB-
Small for gestational age (weight)1.72 [0.28, 10.55]-1 study564not evaluable ROB-

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neonatal infections0.37 [0.09, 1.48]-1 study1064not evaluable ROB-

Hide endpoints reported in only one study ...